BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. (2017)
Attributed to:
Glasgow Molecular Pathology (GMP) Node
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2017.40
PubMed Identifier: 28291774
Publication URI: http://europepmc.org/abstract/MED/28291774
Type: Journal Article/Review
Volume: 116
Parent Publication: British journal of cancer
Issue: 8
ISSN: 0007-0920